JXR (01951), a leading Chinese assisted reproductive services group, has officially launched its Southern Headquarters in Shenzhen on March 23. The new headquarters will adopt a "one hospital, two centers" structure, comprising Shenzhen Zhongshan Maternity Hospital, Hong Kong Grateful Medical Center, and the JXR Medical Technology Innovation Center. This setup is designed to continuously introduce medical resources from Southeast Asia, Europe, and the United States, establishing JXR's strategic hub to serve the Greater Bay Area and extend its reach internationally.
The establishment of JXR's Southern Headquarters in Shenzhen represents both a strategic move to capitalize on development opportunities in the Greater Bay Area and an effort to support the region's goal of building a high-quality living environment that is conducive to living, working, and tourism. Moving forward, JXR will strengthen resource integration and regional coordination with its Chengdu headquarters and Southern Headquarters as dual cores, further enhancing its integrated assisted reproductive services and women’s whole-life-cycle care capabilities, according to Lü Rong, Co-CEO of JXR.
Amid ongoing demographic shifts, assisted reproduction is entering a period of policy opportunities. China is currently undergoing critical adjustments in its population structure. A white paper released on March 21 by global consulting firm Frost & Sullivan, titled "Current Status and Future Trends of China’s Assisted Reproduction Industry in 2026," indicates that China’s infertility rate reached 18% in 2025, affecting over 60 million couples, with trends pointing toward older age and greater complexity.
Against this backdrop, national and societal efforts to improve the system of fertility support policies are intensifying. Assisted reproductive technology is gradually transitioning from a "supplementary medical service" to "an important component of the fertility support system," becoming a key pillar in building a fertility-friendly society.
As a leading enterprise in China’s assisted reproduction sector, JXR has been deeply involved in the industry for 25 years, having completed approximately 300,000 assisted reproductive cycles. The company ranks among the top nationwide in core indicators such as cycle volume and success rates. JXR is well-positioned to contribute to the development of a fertility-friendly society.
Leveraging the relocation of Shenzhen Zhongshan Maternity Hospital to its new campus, JXR has formally established the strategic position of its Southern Headquarters. The new hospital, located on Caitian Road in Shenzhen’s Futian District, offers four times the floor space of its previous facility, making it the largest assisted reproduction medical institution in the Greater Bay Area.
A JXR representative stated that, centered around the new hospital campus, the Southern Headquarters will synergize the service and research strengths of the Hong Kong Grateful Medical Center and the JXR Medical Technology Innovation Center. It will introduce leading industry technologies, academic expertise, and management resources from Southeast Asia, Europe, and the United States, serving the Greater Bay Area while expanding its influence across Southeast Asia and international markets.
JXR is also continuously strengthening its talent foundation. Following the operational launch of the new Shenzhen Zhongshan Maternity Hospital campus, several renowned industry experts and physicians have joined, including Li Baoxing, a recognized "Lingnan Famous Doctor" and former deputy director of the Shenzhen University Urology Research Institute.
The Frost & Sullivan white paper further indicates that between 2020 and 2030, driven by an increasing proportion of age-related infertility and higher treatment penetration rates, China's assisted reproduction market is in a phase of demand release, with market size growing from RMB 23.5 billion to RMB 63 billion. As the macroeconomic environment improves and delayed demand is realized, the period from 2026 to 2027 is expected to be a key inflection point for the industry's transition from adjustment to recovery, leading to a gradual market rebound.
Mao Hua, Senior Partner and Managing Director at Frost & Sullivan, stated that the assisted reproduction industry will continue to develop driven by technological innovation, digital application, and service model optimization. Leading institutions will enhance treatment success rates and patient experience by promoting breakthroughs in key technologies and upgrading clinical practices.
The establishment of the Southern Headquarters will further accelerate the release of JXR's research and technological capabilities. According to Wang Weipeng, CEO of JXR Technology, the company has pioneered the launch of an AI-powered operating system for assisted reproduction, which has been implemented at Morula, Indonesia's largest assisted reproduction platform.
JXR is increasing its investment in research and development, promoting the clinical application of cutting-edge technologies such as AI embryo assessment, time-lapse image analysis, and in vitro maturation of immature oocytes for IVF. The company is leading the exploration of practical pathways for "AI + assisted reproduction" and has already achieved multiple clinical application outcomes.
Mao Hua believes that against the backdrop of demographic changes, improved fertility support policies, and continuous advancements in assisted reproductive technology, China's assisted reproduction industry remains in a long-term development phase. Leveraging its clinical technology, service capabilities, and international布局, JXR has established a relatively comprehensive competitive advantage system, solidifying its position as a top-tier institution in China's assisted reproduction industry. Following the launch of the Southern Headquarters, and supported by its cross-regional operational network and scaled business foundation, JXR is building a moat underpinned by three pillars: technological depth, service breadth, and international stature.